Suppr超能文献

使用组织型纤溶酶原激活剂-妥布霉素封管预防导管相关菌血症

Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks.

作者信息

Onder Ali Mirza, Chandar Jayanthi, Billings Anthony, Simon Nancy, Gonzalez JoAnn, Francoeur Denise, Abitbol Carolyn, Zilleruelo Gaston

机构信息

West Virginia University, WVU/HSC, Morgantown, 26506-9214, USA.

出版信息

Pediatr Nephrol. 2009 Nov;24(11):2233-43. doi: 10.1007/s00467-009-1235-5. Epub 2009 Jul 10.

Abstract

This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.

摘要

本回顾性研究旨在调查组织型纤溶酶原激活剂-妥布霉素抗生素封管液(TPA/妥布霉素ABL)对长期血液透析高危儿童预防导管相关菌血症(CRB)的有效性。在最初的6个月(阶段1),确定了高危组。这些患者在接下来的6个月(阶段2)每次血液透析治疗后接受TPA/妥布霉素ABL预防。在第三个6个月期间(阶段3),预防方案改为每周应用一次。主要终点是CRB和无感染导管存活情况。共有16412个导管日,43名儿童发生95例CRB。CRB发生率为5.8/1000导管日。在高危组中使用预防性TPA/妥布霉素ABL时,观察到CRB发生率显著降低(P = 0.0201)。与每周一次相比,每次血液透析后应用预防性ABL时CRB有减少趋势(P = 0.0947)。在阶段1,高危组的导管存活时间比平均风险组短(P < 0.0001)。然而,在患者接受TPA/妥布霉素ABL预防期间,高危组导管的总体存活和无感染存活均显著改善,与平均风险组导管的结果相似,且差异无统计学意义(分别为P = 0.5571和P = 0.9711)。总之,TPA/妥布霉素ABL可能有效降低CRB发生率,这可能延长高危组导管的总体存活和无感染存活时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验